Daxor Corporation (DXR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Daxor Corporation stock (DXR) is currently trading at $10.23. Daxor Corporation PE ratio is 6.67. Daxor Corporation PS ratio (Price-to-Sales) is 2388.71. Analyst consensus price target for DXR is $22.50. WallStSmart rates DXR as Underperform.
- DXR PE ratio analysis and historical PE chart
- DXR PS ratio (Price-to-Sales) history and trend
- DXR intrinsic value — DCF, Graham Number, EPV models
- DXR stock price prediction 2025 2026 2027 2028 2029 2030
- DXR fair value vs current price
- DXR insider transactions and insider buying
- Is DXR undervalued or overvalued?
- Daxor Corporation financial analysis — revenue, earnings, cash flow
- DXR Piotroski F-Score and Altman Z-Score
- DXR analyst price target and Smart Rating
Daxor Corporation
📊 No data available
Try selecting a different time range
DXR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Daxor Corporation (DXR)
DXR trades at a significant discount to its Graham intrinsic value of $76.75, offering a 84% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Daxor Corporation (DXR) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/book, eps growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Daxor Corporation (DXR) Key Strengths (4)
Earnings per share surging 329.30% year-over-year
Keeps $34359 of every $100 in revenue as net profit
Every $100 of equity generates $23 in profit
Trading at 1.39x book value, attractively priced
Supporting Valuation Data
Daxor Corporation (DXR) Areas to Watch (5)
Losing money on operations
Revenue declining -82.60%, a shrinking business
Very expensive at 2388.7x annual revenue
Very low institutional interest at 1.45%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Daxor Corporation (DXR) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Profit Margin, Return on Equity. Valuation metrics including Price/Book (1.39) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 22.50%, Profit Margin at 34359.00%. Growth metrics are encouraging with EPS Growth at 329.30%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (2388.71) suggest expensive pricing. Growth concerns include Revenue Growth at -82.60%, which may limit upside. Profitability pressure is visible in Operating Margin at -9661.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 22.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -82.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DXR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DXR's Price-to-Sales ratio of 2388.71x trades 1807% above its historical average of 125.28x (97th percentile), historically expensive. The current valuation is 5% below its historical high of 2507.42x set in Mar 2026, and 20617% above its historical low of 11.53x in Feb 2018. Over the past 12 months, the PS ratio has expanded from ~1050.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Daxor Corporation (DXR) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Daxor Corporation faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 26,690 with 83% decline year-over-year. Profit margins are strong at 34359.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 22.5% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Revenue contracted 83% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -297,470, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Daxor Corporation.
Bottom Line
Daxor Corporation faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Daxor Corporation(DXR)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.